Patent covers brilaroxazine use for treating Pulmonary Fibrosis-Similar patents have also been granted in key markets around the world ...

Tenax Therapeutics ( ($TENX) ) has released its Q3 earnings. Here is a breakdown of the information Tenax Therapeutics presented to its investors.

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary ...

Data showed that the expression (activity) of the ABCA3 gene was lower in IPAH patients, while that of the SMAD9 gene was ...

Growth is driven by rising COPD cases due to smoking and pollution, and enhanced therapeutic options like bronchodilators and biologics. Significant investments are improving diagnosis and treatment.

The pulmonary emphysema market is poised for steady growth driven by rising COPD prevalence, an aging global population, and greater diagnostic awareness. Advances in inhaled therapies, targeted ...

Adequate management of COPD is important because hospitalisation for an acute exacerbation of COPD (AECOPD) is associated ...

AstraZeneca's hopes of a big new indication for respiratory drug Fasenra in chronic obstructive pulmonary disease (COPD) have been dashed by a negative phase 3 trial. The RESOLUTE study of IL-5 ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) acquisition. Verona Pharma is now a ...

This research also helps explain why chronic inflammation—caused by smoking, pollution, or long-term infections—has long been ...

The Union government has directed states and Union territories to establish a robust public health response, including ...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the ...